• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cardiol Therapeutics Inc. - Class A Common Shares (NQ:CRDL)

0.9973 -0.0027 (-0.27%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cardiol Therapeutics Inc. - Class A Common Shares

< Previous 1 2 Next >
News headline image
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
December 01, 2025
(December 1, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company advancing anti-inflammatory and 
Via PressReach
News headline image
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
December 01, 2025
Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac... 
Via Newsfile
News headline image
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
August 06, 2025
(August 6, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory 
Via PressReach
News headline image
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
April 16, 2025
Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by... 
Via Newsfile
News headline image
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Appoints Terry Lynch to Board, Grants Options
March 27, 2025
Via Investor Brand Network
News headline image
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart
February 20, 2025
Toronto, Ontario--(Newsfile Corp. - February 20, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a... 
Via Newsfile
News headline image
“Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation – AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances”
December 06, 2024
Via AB Newswire
News headline image
Thanksgiving Week Oversold Stocks to Watch: CRDL, QBTS, PRSO, RGTI & More!
November 25, 2024
Via AB Newswire
News headline image
“Game-Changers to Watch CRDL, RMSG, WORX, PET and more…Innovative Companies inside”
November 21, 2024
Via AB Newswire
Topics Economy
News headline image
Cardiol Therapeutics (Nasdaq: CRDL) Advances Orphan Drug Designation for CardiolRx™ at the American Heart Association…more stocks inside…
November 21, 2024
Via AB Newswire
News headline image
Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!
November 18, 2024
Via AB Newswire
News headline image
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
November 18, 2024
Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week studyEpisodes of pericarditis per year substantially... 
Via Newsfile
News headline image
“Emerging Innovators Transforming Global Markets: IPA, CRDL, KXIN, GNS, PRSO in Sectors”
November 13, 2024
Via AB Newswire
Topics Electric Vehicles
Biotech and Technology Giants Drive Innovation Across Pharma, Medical Devices, and Industrial Automation CRDL, MODD, CYN
November 07, 2024
Via AB Newswire
“Trump Media (NASDAQ: DJT) Surges on Election Day as SmallCap Stocks CRDL, ALBT, ZVSA, PRSO Emerge”
November 05, 2024
Via AB Newswire
Topics Government
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”
October 28, 2024
Via AB Newswire
Topics Artificial Intelligence
Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX
October 23, 2024
Via AB Newswire
Topics Intellectual Property
Cardiol Therapeutics’ (NASDAQ: CRDL) CardiolRx™ Addresses Urgent Medical Condition Myocarditis, a Leading Cause of Sudden Cardiac Death see more stocks inside…
October 22, 2024
Via AB Newswire
“Cardiol Therapeutics (NASDAQ: CRDL) Myocarditis Breakthrough Featured on Fox Business: CardiolRx™ Poised for Medical Impact more stocks inside…”
September 12, 2024
Via AB Newswire
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
June 17, 2024
In a phenomenal year marked by over +180% gains in its stock price, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) added another feather to its cap last week with the announcement of its Phase II... 
Via TheNewswire.com
News headline image
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
June 13, 2024
Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce... 
Via Newsfile
Sector Spotlight: Orphan Drug Developers With Significant Upside
June 03, 2024
Via AB Newswire
Topics ETFs
Sector Spotlight: Orphan Drug Developers With Significant Upside
June 03, 2024
The biotech sector is finally beginning to recover following a two year stretch of underperformance that was largely driven by rising interest rates and other macro factors. Biotech has a track record... 
Via TheNewswire.com
Topics ETFs
Analysts Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL)
May 28, 2024
Via AB Newswire
News headline image
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
February 21, 2024
This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)... 
Via Newsfile
News headline image
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
February 15, 2024
This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 15, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)... 
Via Newsfile
News headline image
Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
November 01, 2023
Toronto, Ontario--(Newsfile Corp. - November 1, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a... 
Via Newsfile
Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
October 13, 2023
Via Get News
Topics Death
Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
October 13, 2023
Toronto, ON, October 13, 2013 (PlatoData via 500NewsWire) -- In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary... 
Via TheNewswire.com
Topics Death
News headline image
Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction
October 10, 2023
Results Demonstrate the Active Pharmaceutical Ingredient in Cardiol's Novel CRD-38 Formulation Attenuates Harmful Fat Distribution and Key Markers of Cardiac... 
Via Newsfile
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap